Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G; Nordic Study Group for Myeloproliferative Disorders. Samuelsson J, et al. Cancer. 2006 Jun 1;106(11):2397-405. doi: 10.1002/cncr.21900. Cancer. 2006. PMID: 16639737 Free article. Clinical Trial.
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, Mesa RA. Geyer HL, et al. Among authors: samuelsson j. Cancer. 2016 Jun 15;122(12):1888-96. doi: 10.1002/cncr.30013. Epub 2016 Apr 12. Cancer. 2016. PMID: 27070130 Free article.
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, Andreasson B, Birgegård G, Linder O, Malm C, Markevärn B, Nilsson L, Samuelsson J, Granath F, Landgren O. Björkholm M, et al. Among authors: samuelsson j. J Clin Oncol. 2011 Jun 10;29(17):2410-5. doi: 10.1200/JCO.2011.34.7542. Epub 2011 May 2. J Clin Oncol. 2011. PMID: 21537037 Free PMC article.
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, Fernandes S, Bareford D, Knapper S, Samuelsson J, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Hasselbalch HC. Andersen CL, et al. Among authors: samuelsson j. Br J Haematol. 2013 Aug;162(4):498-508. doi: 10.1111/bjh.12416. Epub 2013 Jun 11. Br J Haematol. 2013. PMID: 23758082 Free article. Clinical Trial.
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
Andersen CL, Bjørn ME, McMullin MF, Harrison C, Samuelsson J, Ejerblad E, Zweegman S, Fernandes S, Bareford D, Knapper S, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Skov V, Thomassen M, Kruse T, Grønbæk K, Hasselbalch HC. Andersen CL, et al. Among authors: samuelsson j. Leuk Res. 2014 Jul;38(7):816-21. doi: 10.1016/j.leukres.2014.04.002. Epub 2014 Apr 14. Leuk Res. 2014. PMID: 24836761 Clinical Trial.
236 results